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Development of mucosal vaccines strongly relies on an efficient delivery system and, over the years, a variety of
approaches based on phages, bacteria or synthetic nanoparticles have been proposed to display and deliver
antigens. The spore of Bacillus subtilis displaying heterologous antigens has also been considered as a mucosal
vaccine vehicle, and shown able to conjugate some advantages of live microrganisms with some of synthetic
nanoparticles. Here we review the use of non-recombinant spores of B. subtilis as a delivery system for mucosal
immunizations. The non-recombinant display is based on the adsorption of heterologous molecules on the spore
surface without the need of genetic manipulations, thus avoiding all concerns about the use and environmental
release of genetically modified microorganisms. In addition, adsorbed molecules are stabilized and protected by the
interaction with the spore, suggesting that this system could reduce the rapid degradation of the antigen, often
observed with other delivery systems and identified as a major drawback of mucosal vaccines.
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Currently licensed vaccines are delivered by one of five
main administration routes. The intramuscular route is the
most common one and several vaccines, such as hepatitis
A and B, rabies, influenza, diphtheria, tetanus and per-
tussis, are delivered by this approach. Subcutaneous and
intradermal routes are also common and used, for ex-
ample, for measles-mumps-rubella-yellow fever and BCG-
rabies vaccinations, respectively. The remaining two routes
deliver antigens to the nasal or intestinal mucosal surfaces.
The intranasal route is used, for example, for live attenu-
ated influenza viruses while the oral route is used for polio-
myelitis, cholera, rotavirus and typhoid fever vaccinations.
Mucosally administered vaccines have a number of
potential advantages over injectable vaccines: no risk of
transmission of blood-borne diseases; no need of trained
personnel to administer and the possibility to elicit an im-
mune response at the portal of entry of most pathogens
[1]. However, despite these potential advantages and early
success with the oral polio vaccine more than 50 years ago,
injectable vaccines are widely more common than mucosal
ones [2]. This is in part due to a number of drawbacks* Correspondence: ericca@unina.it
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unless otherwise stated.associated with currently available mucosal vaccines, such
as poor antigen adsorption, rapid antigen degradation on
the mucosal surfaces and lack of safe and effective mucosal
adjuvants [2]. Recent advances in mucosal immunology,
and recent success with the development of mucosal
vaccines against influenza and rotavirus infections have
renewed interest in the development of a new generation
of mucosal vaccines. Public health organizations are urging
the scientific community to focus on the development of
efficient systems to deliver antigens to mucosal sites that
facilitate uptake by local antigen-presenting cells, and on
the discovery of safe and effective mucosal adjuvants that
enhance the protective mucosal immune response.
We review here the use of non-recombinant spores of
Bacillus subtilis as a delivery system for mucosal immuni-
zations. Spores of B. subtilis are extremely resistant and
stable, easy to manipulate and are known to interact with
immune cells inducing protective, antigen-specific immune
responses [3]. A variety of antigens have been displayed on
the surface of recombinant B. subtilis spores and used to
immunize animal models through the nasal and/or oral
route [4]. Like other display systems, also the spore-based
approach rely on the genetic engineering of the host. This
raises concerns over the use of live genetically modified mi-
croorganisms, their release into nature and their clearancetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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tacle a non-recombinant approach to display heterologous
proteins on the spore surface has been recently proposed.The spore of Bacillus subtilis
Spores are quiescent cells mainly produced by members
of two genera of Gram-positive bacteria, the aerobic or
facultative anaerobic Bacilli and the anaerobic Clostridia
[6]. The common feature of these organisms is the abil-
ity to respond to harsh environmental conditions differ-
entiating a spore from a vegetative cell. Because of its
peculiar structure the spore is extremely stable and sur-
vives indefinitely to the absence of water and nutrients,
to the presence of lytic enzymes and toxic chemicals, of
UV irradiation and to extremes of temperature and pH
[7]. However, in the presence of water, nutrients and
favourable environmental conditions, the spore germi-
nates generating a cell able to duplicate vegetatively and,
eventually, to re-sporulate. The processes of sporulation
and germination in Bacillus subtilis, the model system
for spore-formers, have been recently reviewed [8,9].
In B. subtilis the spore structure has been studied in
details and shown to be formed by a dehydrated cyto-
plasm (core) surrounded by several protective layers: the
thick peptidoglycan-like cortex, the multilayered, pro-
teinaceous coat and the crust, the outermost layer
formed of proteins and glycans [7]. Interestingly, several
spore surface proteins have the ability to self-assemble
[10,11] and the entire spore can self-assemble into func-
tional structures [12].
Despite their metabolic quiescence, spores are dynamic
structures able to respond to changes in relative humidity
by expanding and shrinking [13]. It has been measured
that in response to humidity the B. subtilis spore can
change its diameter by as much as 12% [14,15]. Such vari-
ations have been recently used for energy conversion and
have proposed the spore as a building block for novel
stimuli-responsive materials with potential applications in
energy harvesting and storage [12].
Spores of several aerobic species are ubiquitous in nature
[16]. In recent years large numbers of aerobic spore-
formers, including members of the B. subtilis species, have
also been found associated to the human and animal gut
[17,18]. It has been shown that ingested spores of B. subti-
lis safely transit the stomach, germinate and proliferate in
the upper part of the intestine [19]. In the lower part of
the intestine the cells sporulate again, thus performing an
entire life cycle in the animal gastro-intestinal tract (GIT)
[20]. In the GIT B. subtilis interacts with intestinal epithe-
lial and immune cells [21–23], contributes to the normal
development of the gut-associated lymphoid tissue (GALT)
[24] and protects the host from enteropathogens [25].
Such interactions with intestinal cells are the base for theuse of several isolates of B. subtilis in commercial probiotic
preparations (Table 1) [20].
Recombinant spore-surface display
The rigidity and compactness of the spore surface together
with its proteinaceous composition suggested the possibil-
ity of using surface proteins to fuse and anchor heterol-
ogous proteins. The genetic system developed to this aim
is summarized in Figure 1 and is based on the: i) construc-
tion of a gene fusion between DNA fragments coding for
an antigen and a surface protein, with transcriptional and
translational signals of the latter controlling the expression
of the fusion; ii) integration of the fusion on the B. subtilis
chromosome to grant genetic stability; iii) expression of
the gene fusion in the mother cell and the assembly of the
chimera around the forming spore; iv) purification of the
recombinant spore carrying the chimera stably associated
to the spore surface. This system was initially developed
by using the spore surface protein CotB as a carrier and
the C fragment of the tetanus toxin (TTFC) of Clostrid-
ium tetani as a model antigen and was shown able to
display an average of 1.5 × 103 recombinant molecules per
spore [26]. Spore-exposed TTFC molecules were able to
induce an antigen-specific immune response and to pro-
tect orally immunized mice in challenge experiments [27].
The immune response induced by spores displaying TTFC
was not dependent on the ability of the spore to germin-
ate in the GIT of the immunized animals, as shown by
immunization experiments with mutant spores displaying
TTFC but unable to germinate [28]. Over the years the
same approach has been utilized to display several differ-
ent antigens with various spore surface proteins as carriers
(for a recent review see 4). In several cases the recombin-
ant spores have been tested as mucosal vaccines in animal
models and proved able to induce specific and protective
immune responses (for a review see 3). Recently, a set of
plasmids have been developed to facilitate the construc-
tion of gene fusions using selected cot genes as carriers
[29]. A useful development of some of these plasmids is
that they allow the integration on the B. subtilis chromo-
some without the need to select for an antibiotic marker.
By this system the recombinant strains display a heterol-
ogous antigen but do not contain an antibiotic-resistance
gene [29].
Non-recombinant spore-surface display
The display strategy summarized in Figure 1, even when
it does not involve an antibiotic-resistance gene [29], re-
lies on the genetic engineering of the host and involves
the release into nature of a recombinant microorganism.
This is considered as a major drawback, especially when
the display system is designed for human or animal use
[5]. Therefore, non-recombinant approaches are highly
desirable and their development is strongly encouraged
Table 1 Examples of commercial products containing spores of B. subtilis for human or animal use1
Product Spores/dose Manufacturer Use
Bibactyl 107-108 Tediphar Corporation (VietNam) Human
Bio-Kult NS2 Protexin Health Care (UK) Human
Biobaby 3 × 106 plus other bacteria Ildong Pharma (Korea) Human
BioGrow 1.6 × 109 plus other bacteria Provita Eurotech (UK) Poultry, calves, swine
BioPlus 1.6 × 109 plus other bacteria Christian Hansen (Denmark) Piglets, poultry
Biosporin NS2 Bioparm (Ukrine) Human
Biostart NS2 Microbial Solutions (South Africa) Aquaculture
Biosubtyl DL 107-108 IVAC (VietNam) Human
BioZyme-Aqua 1 × 108 Sino-Aqua Corp. (Taiwan) Aquaculture
Ildong Biovita 3 × 106 plus other bacteria Ildong Pharma (Korea) Human
Lactipan Plus 2 × 109 Ist. Biochimico Italiano (Italy) Human
Medilac-Vita 1 × 108 plus other bacteria Hanmi Pharmaceutical (China) Human
Nature’s First Food NS2 Nature’s First Law (USA) Human
Neolactoflorene NS2 Newpharma (Italy) Human
Pastylbio 1 × 108 Pasteur Institute (VietNam) Human
Primal defense NS2 Garden of Life (USA) Human
Promarine NS2 Sino-Aqua (Taiwan) Aquaculture
1Adapted from [20]; 2Not Specified.
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approach to display heterologous proteins on the spore
surface has also been developed. As summarized in
Figure 2, upon incubation of spores with a purified antigen
part of the antigen molecules are stably bound to the
spore surface. Huang et al. [30] have reported that four an-
tigens (TTFC of C. tetani, PA of B. anthracis, Cpa of C.
perfringens and glutathione S transferase from Shistosomas
japonica) were efficiently adsorbed to spores. Adsorption
was more efficient at acidic conditions (pH 4.0) and less
efficient or totally inhibited at pH 7.0 or 10.0, respectively.
Adsorption was not dependent on any specific coat pro-
teins but, rather, due to a combination of electrostatic and
hydrophobic interactions between spores and antigen [30].
Importantly, antigen-adsorbed spores were able to induce
specific and protective immune responses in nasally im-
munized mice [30].
In a similar way also a model enzyme, the β-galactosidase
of Alicyclobacillus acidocaldaricus, was efficiently adsorbed
to B. subtilis spores [31]. Also in this case adsorption was
dependent of the pH of the binding solution and was more
efficient at acidic than neutral or basic conditions. This
study, although not performed with an antigen, revealed
some properties of spore adsorption that could turn out po-
tentially useful for the development of new mucosal vac-
cines: 1) the adsorbed enzyme was more stable than the
unbound, free enzyme at both high temperatures and low
pH values, suggesting that the interaction with the spore
stabilizes and protects the heterologous protein; 2) mutant
spores with a strongly altered surface adsorbed the enzymemore efficiently than isogenic wild type spores [31]. B. sub-
tilis spores are known to be negatively charged and in an
aqueous environment behave like almost infinite ionic res-
ervoirs accumulating billions of protons (approximately 2 ×
1010 per spore) [32]. An expected consequence of the re-
duced number of free protons in solution is a pH increase
and, indeed, 2 × 109 spores were able to raise the pH of
pure water from 5.98 to over 7.00 [31]. The same amounts
of mutant spores with either a strongly altered (cotH) or a
totally lacking (cotE) outer coat did not alter the pH of pure
water, indicating that they did not attract protons and,
therefore, are not (or less) negatively charged [31]. Since
these mutant spores adsorb β-Gal more efficiently than
wild type spores, the negative electric charge of the spore is
not a major determinant of β-Gal adsorption [31]. More
recently another enzyme, the cellobiose 2-epimerase of
Caldicellulosiruptor saccharolyticus has been adsorbed on
the spore surface [33]. Also in this case, the spore-
immobilized enzyme showed a higher pH and thermal sta-
bility than the free enzyme. Adsorption was very stable
and the enzyme detached from the spore surface only by a
drastic treatment with 1.0 M NaCl at pH 1.0 [33].
Live as well as heat-inactivated spores were also shown
able to bind influenza H5N1 virions (NIBRG-14; clade
1) [34]. Groups of mice intranasally immunized with
killed spores adsorbed with NIBRG-14 were able to fully
protect the animals in a challenge experiment with a le-
thal dose (20 times the LD50) of the virus. Particularly
interesting is the observation that killed spores without
any adsorbed virion were able to partially protect (60%)
Figure 1 Strategy of recombinant spore-surface display. A) A gene fusion is constructed between DNA coding for a spore surface protein
(gray) and for an antigen (black). The fusion is under the transcriptional and translational signals of the spore surface gene. B) The gene fusion
is cloned into an integrative plasmid next to an antibiotic-resistance gene cassette (AbR) and between two parts of a non-essential gene of
B. subtilis. The gene fusion is integrated on the B. subtilis chromosome by a double cross over between homologous DNA present on the
integrative plasmid and on the chromosome, interrupting the non-essential gene. C) During sporulation the gene fusion is expressed in the
mother cell and the chimera assembled around the forming spore. D) At the end of sporulation the mother cell lyses releasing the mature
spore with the antigen stably anchored to its surface.
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response, suggesting for the spore an adjuvant role for
H5N1 vaccination [34].
Spores of B. subtilis have also been used to adsorb two
Mycobacterium tuberculosis antigens: i) MPT64, a 25-kDa
secreted protein, not produced by attenuated strains, char-
acterized by a highly immunogenic activity and shown
able to confer partial protection in challenge experiments
with a mouse models [35]; and ii) the chimera Acr-Ag85B,
formed by two antigens, Acr preferentially recognized by
latently infected individuals and Ag85B, one of the most
protective antigens of M. tuberculosis. As in the previous
cases, adsorption of the two M. tuberculosis antigens was
pH-dependent. Intranasally administered spores were able
to reach the alveoli and to induce both humoral andcellular immune responses [36]. Immunized animals were
protected in a challenge experiment and presented re-
duced mycobacterial loads in their lungs and spleens, con-
firming that mucosal vaccinations are particularly effective
against pathogens entering the animal body through the
mucosal surfaces [36].
Recombinant vs. non-recombinant spore-surface display
A recent report has compared the efficiency of recombin-
ant and non-recombinant spore display using as a model
antigen the binding subunit of the heat-labile toxin (LTB)
of Escherichia coli [37]. LTB displayed by both strategies
was able to induce a specific immune response in muco-
sally immunized mice [37,38]. An average of 9.6 × 10-5 pg
of LTB/spore, corresponding to approx. 200 ng of LTB in
Figure 2 Strategy of non-recombinant spore-surface display. Purified spores and antigen are reacted at 25°C in an acidic reaction buffer
(pH 4.0). After the adsorption reaction spore-bound and free antigen are separated by centrifugation.
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ant approach (CotC-LTB), while the same number of
spores was able to display up to 5.5 μg of LTB by the non-
recombinant approach [37]. The 25-fold higher efficiency
of display obtained with the non-recombinant strategy
than with the recombinant one was further improved
using mutant spores with an altered outer coat (cotH mu-
tant spores). 2 × 109 cotH spores adsorbed approx. 14 μg
of LTB, about 70-fold more efficient than the antigen dis-
played by the recombinant approach [37]. The increased
efficiency of display of non-recombinant vs. recombinantapproach is particularly relevant since it allows to reduce
the number of spores needed to induce an immune re-
sponse. Effective immunizations have been obtained in
mice dosing the animals with at least nine doses of
1.0 × 1010 recombinant spores [38]. Scaling up that num-
ber to immunize humans would be extremely difficult or
even not realistic, making necessary to use a more efficient
display systems.
An additional advantage of the non-recombinant sys-
tem over the recombinant one is that only the former
approach allows the display of a multimeric antigen in
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toxin, forms pentamers and only as a pentamer can bind
its natural receptor, the GM1 ganglioside [39]. While
only LTB monomers can be displayed by the recombin-
ant approach on the surface of Streptococcus gordonii
[40] or of B. subtilis spores, LTB pentamers can be dis-
played by the non-recombinant approach on the spore
surface (Figure 3) [37]. This aspect is crucial since the
immunostimulatory activity of LTB largely depends on
its ability to bind to its receptor, which only recognizes
the pentamer via non-covalent associations. Pentamer
formation and interaction with GM1 result in enhanced
targeting and access to MHC compartments [41] with
the consequent increased activation of antigen present-
ing cells and T cells [42].Figure 3 Display of a multimeric antigen on the spore surface. Purified s
are reacted with the purified receptor (GM1). Spores are visualized by immuno
conjugated secondary antibody [36]. The same microscopy field is observed b
images is also shown.Advantages of the non-recombinant spore-based delivery
system
The use of B. subtilis spores, both by the recombinant
and non-recombinant approach, has several advantages
over other cell- or phage-based display systems. A first
advantage comes from the safety of B. subtilis spores for
human use. The widespread utilization of spores of this
species in commercial probiotic preparations and in
traditional food preparations (Table 1) represents an ex-
ceptional safety record for the B. subtilis species. Other
advantages come from the well documented robustness
of the spore which grants high stability to the display
system even after a prolonged storage [43]. The stability
of the delivery system is an important requirement in
developing new mucosal vaccine, especially if intendedpores are reacted with the LTB pentamers. Spore-adsorbed pentamers
fluorescence microscopy with anti-GM1 primary antibody and Texas red
y phase contrast and fluorescence microscopy. The merge of the two
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where poor distribution and storage conditions are
major limitations.
To these advantages the non-recombinant display ap-
proach adds additional favourable properties. No genetic
manipulation is required for the display, eliminating
concerns over the use and release of recombinant micro-
organisms. Spore-adsorbed proteins are stabilized and
protected by the interaction with the spore and are more
stable that free proteins to high temperatures and acidic
pH conditions [31], suggesting that spore-exposed anti-
gens may have a longer half-life at mucosal surfaces.
The non-recombinant approach is more efficient than
the recombinant spore display system, allowing to use up
to 70-fold less spores to deliver a similar amount of anti-
gen. Finally, only the non-recombinant approach allows
the disply of multimeric antigens in their native form, in
turn ensuring the recognition of the natural receptor and
a proper activation of the immune system [37].
Future perspectives
Future developments of the non-recombinant spore dis-
play system will necessarily have to be based on a better
understanding of the mechanisms involved in spore ad-
sorption. A combination of electrostatic and hydrophobic
interactions between spores and passengers have initiallyFigure 4 Combined recombinant and non-recombinant spore-surface dis
molecule adsorbed to the spore. B) Spore displaying streptavidin by the recom
streptavidin-biotin interaction the spore binds to a biotinylated anti-EGFR primabeen suggested as responsible of the adhesion [30]. How-
ever, in the case of β-galactosidase adsorption the role of
electrostatic force has been shown to be not predominant
[31]. It is possible that adsorption is somehow multifactor-
ial and not due to a single mechanism, however, whether
other factors (e.g., van der Waals and capillary forces) are
also involved, how the involved forces are affected by ex-
ternal factors such as humidity, or by properties of the
passenger protein are all relevant questions that still need
to be addressed. Relevant in this frame is the observation
that spores can be studied at a single-cell level by the use
of optical tweezers, thus opening to the possibility of a
deep characterization of the physico-chemical properties
of the spore surface [44].
A future and exciting extension of recombinant and
non-recombinant spore display systems comes from a re-
cent report showing that: i) the two approaches can be
used in combination, and ii) non-proteinaceous molecules
can also be adsorbed to the spore surface [45]. The diter-
pen paclitaxel, a mitotic inhibitor used in cancer therapy
(Figure 4A), was adsorbed on B. subtilis spores already dis-
playing streptavidin as a chimeric fusion to the spore sur-
face protein CotB [45]. The recombinant spores were able
to bind a primary biotinylated antibody specifically react-
ing with the human epidermal growth factor receptor
(EGFR, Cetuximab), thus targeting spores and moleculesplay. A) The diterpen paclitaxel, used as an example of non-proteinaceous
binant approach and paclitaxel by the non-recombinant one. By
ry antibody targeting the spore to the EGFR-exposing cell [43].
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http://www.microbialcellfactories.com/content/13/1/115adsobed to them to the surface of cells exposing EGFR
(Figure 4B) [45]. By this approach spores displaying strep-
tavidin can bind any biotinylated antibody, potentially tar-
geting spores and adsorbed molecules to any potential
target cell.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ER, LB, GC, MDF, RI contributed to literature search and analysis, and
manuscript preparation. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by EU (VII Framework, contract number 613703
and 614088 to ER).
Received: 17 June 2014 Accepted: 31 July 2014
Published: 12 August 2014
References
1. De Magistris MT: Mucosal delivery of vaccine antigens and its advantages
in pediatrics. Adv Drug Deliv Rev 2006, 58:52–67.
2. Woodrow KA, Bennett KM, Lo DD: Mucosal vaccine design and delivery.
Ann Rev Biomed Eng 2012, 14:17–46.
3. Cutting SM, Hong HA, Baccigalupi L, Ricca E: Oral vaccine delivery by
recombinant spore probiotics. Intern Rev Immunol 2009, 28:487–505.
4. Isticato R, Ricca E: Spore Surface Display. In The Bacterial Spore. Edited by
Driks A, Eichemberger P. Washigton DC, US: ASM press; 2014. in press.
5. Detmer A, Glenting J: Live bacterial vaccines—a review and identification
of potential hazards. Microb Cell Fact 2006, 5:23.
6. Fritze D: Taxonomy and systematics of the aerobic endospore forming
bacteria: Bacillus and related genera. In Bacterial Spore Formers. Edited by
Ricca E, Henriques AO, Cutting SM. Norfolk, UK: Horizon Biosience; 2004:17–34.
7. McKenney PT, Driks A, Eichemberger P: The Bacillus subtilis endospore:
assembly and functions of the multilayered coat. Nat Rev Microbiol 2013,
11:33–44.
8. Dworkin J, Shah IM: Exit from dormancy in microbial organisms. Nat Rev
Microbiol 2010, 8:890–896.
9. Higgins D, Dworkin J: Recent progress in Bacillus subtilis sporulation.
FEMS Microbiol Rev 2012, 36:131–148.
10. Tang J, Krajcikova D, Zhu R, Ebner A, Cutting S, Gruber HJ, Barak I,
Hinterdorfer P: Atomic force microscopy imaging and single molecule
recognition force spectroscopy of coat proteins on the surface of
Bacillus subtilis spore. J Mol Recognit 2007, 20:483–489.
11. Ramamurthi KS, Losick R: ATP-driven self-assembly of a morphogenetic
protein in Bacillus subtilis. Mol Cell 2008, 31:406–414.
12. Chen X, Mahadevan L, Driks A, Sahin O: Bacillus spores as building blocks
for stimuliresponsive materials and nanogenerators. Nature Nanotechnol
2014, 9:137–141.
13. Driks A: The dynamic spore. Proc Natl Acad Sci U S A 2003, 100:3007–3009.
14. Plomp M, Leighton TJ, Wheeler KE, Malkin AJ: The high-resolution architecture
and structural dynamics of Bacillus spores. Biophys J 2005, 88:603–608.
15. Sahin O, Yong EH, Driks A, Mahadevan L: Physical basis for the adaptive
flexibility of Bacillus spore coats. J R Soc Interface 2012, 9:3156–3160.
16. Nicholson WL: Roles of Bacillus endospores in the environment. Cell Mol
Life Sci 2002, 59:410–416.
17. Hong HA, To E, Fakhry S, Baccigalupi L, Ricca E, Cutting SM: Defining the
natural habitat of Bacillus spore-formers. Res Microbiol 2009, 160:375–379.
18. Fakhry S, Sorrentini I, Ricca E, De Felice M, Baccigalupi L: Characterisation of
spore forming Bacilli isolated from the human gastrointestinal tract.
J Appl Microbiol 2008, 105:2178–2186.
19. Casula G, Cutting SM: Bacillus probiotics: spore germination in the
gastrointestinal tract. Appl Environ Microbiol 2002, 68:2344–2352.
20. Cutting SM: Bacillus probiotics. Food Microbiol 2011, 28:214–220.
21. Duc LH, Hong AH, Nguyen QU, Cutting SM: Intracellular fate and
immunogenicity of B. subtilis spores. Vaccine 2004, 22:1873–1885.
22. Fujita M, Musch MW, Nakagawa Y, Hu S, Alverdy J, Kohgo Y, Schneewind O,
Jabri B, Chang EB: The Bacillus subtilis quorum-sensing molecule CSFcontribute to intestinal homoestasis via OCTN2, a host cell membrane
transporter. Cell Host Microb 2007, 1:299–308.
23. Ceragioli M, Cangiano G, Esin S, Ghelardi E, Ricca E, Senesi S: Phagocytosis,
germination and killing of Bacillus subtilis spores presenting
heterologous antigens in human macrophages. Microbiology 2009,
155:338–346.
24. Rhee K-J, Sethupathi P, Driks A, Lanning DK, Knight KL: Role of commensal
bacteria in development of gut-associated lymphoid tissue and
preimmune antibody repertoire. J Immunol 2004, 172:1118–1124.
25. D’Arienzo R, Maurano F, Mazzarella G, Luongo D, Stefanile R, Ricca E,
Rossi M: Bacillus subtilis spores reduce susceptibility to Citrobacter
rodentium-mediated enteropathy in a mouse model. Res Microbiol 2006,
157:891–897.
26. Isticato R, Cangiano G, Tran T-H, Ciabattini A, Medaglini D, Oggioni MR,
De Felice M, Pozzi G, Ricca E: Surface display of recombinant proteins on
Bacillus subtilis spores. J Bacteriol 2001, 183:6294–6301.
27. Duc LH, Huynh HA, Fairweather N, Ricca E, Cutting SM: Bacterial spores as
vaccine vehicles. Infect Immun 2003, 71:2810–2818.
28. Mauriello EMF, Cangiano G, Maurano F, Saggese V, De Felice M, Rossi M,
Ricca E: Germination-independent induction of cellular immune response
by Bacillus subtilis spores displaying the C fragment of the tetanus toxin.
Vaccine 2007, 25:788–793.
29. Iwanicki A, Piątek I, Stasiłojć M, Grela A, Lęga T, Obuchowski M, Hinc K: A
system of vectors for Bacillus subtilis spore surface display. Microb Cell
Fact 2014, 13:30.
30. Huang JM, Hong HA, Van Tong H, Hoang TH, Brisson A, Cutting SM:
Mucosal delivery of antigens using adsorption to bacterial spores.
Vaccine 2010, 28:1021–1030.
31. Sirec T, Strazzulli A, Isticato R, De Felice M, Moracci M, Ricca E: Adsorption
of beta-galactosidase of Alicyclobacillus acidocaldarius on wild type and
mutants spores of Bacillus subtilis. Microb Cell Fact 2012, 11:100.
32. Kazakov S, Bonvouloir E, Gazaryan I: Physicochemical characterization of
natural ionic microreservoirs: Bacillus subtilis dormant spores. J Phys
Chem 2008, 112:2233–2244.
33. Gu J, Yang R, Hua X, Zhang W, Zhao W: Adsorption-based immobilization
of Caldicellulosiruptor saccharolyticus cellobiose 2-epimerase on Bacillus
subtilis spores. Biotechnol Appl Biochem 2014. in press doi:10.1002/bab.1262.
34. Song M, Hong HA, Huang JM, Colenutt C, Khang DD, Nguyen TV, Park SM,
Shim BS, Song HH, Cheon IS, Jang JE, Choi JA, Choi YK, Stadler K, Cutting
SM: Killed Bacillus subtilis spores as a mucosal adjuvant for an H5N1
vaccine. Vaccine 2012, 30:3266–3277.
35. Delogu G, Howard A, Collins FM, Morris SL: DNA vaccination against
tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein
enhances antimycobacterial immunity. Infect Immun 2000, 68:3097–3102.
36. Reljic R, Sibley L, Huang JM, Pepponi I, Hoppe A, Hong HA, Cutting SM:
Mucosal vaccination against tuberculosis using inert bioparticles.
Infect Immun 2013, 81:4071–4080.
37. Isticato R, Sirec T, Treppiccione L, Maurano F, De Felice M, Rossi M, Ricca E:
Non-recombinant display of the B subunit of the heat labile toxin of
Escherichia coli on wild type and mutant spores of Bacillus subtilis.
Microb Cell Fact 2013, 12:98.
38. Mauriello EMF, Duc LH, Isticato R, Cangiano G, Hong HA, De Felice M, Ricca E,
Cutting SM: Display of heterologous antigens on the Bacillus subtilis spore
coat using cotc as a fusion partner. Vaccine 2004, 22:1177–1187.
39. Kim J-M, Park S-M, Kim J-A, J-a P, M-h Y, Kim N-S, Bae J-L, Park GS, Jang J-S,
Yang M-S, Kim D-H: Functional pentameric formation via coexpression of
the Escherichia coli heat-labile enterotoxin B subunit and its fusion
protein subunit with a Neutralizing Epitope of ApxIIA Exotoxin improves
the mucosal immunogenicity and protection against challenge by
Actinobacillus pleuropneumoniae. Clin Vaccine Immunol 2011, 18:2168–2177.
40. Ricci S, Medaglini D, Rush CM, Marcello A, Peppoloni S, Manganelli R, Palú
G, Pozzi G: Immunogenicity of the B monomer of Escherichia coli heat
labile toxin expressed on the surface of Streptococcus gordonii. Infect
Immun 2000, 68:760–766.
41. Nashar TO, Webb HM, Eaglestone S, Williams NA, Hirst TR: Potent
immunogenicity of the B subunits of Escherichia coli heat-labile
enterotoxin: receptor binding is essential and induces differential
modulation of lymphocyte subsets. Proc Natl Acad Sci U S A 1996,
93:226–230.
42. Nashar TO, Betteridge ZE, Mitchell RN: Evidence for a role of ganglioside
GM1 in antigen presentation: binding enhances presentation of
Ricca et al. Microbial Cell Factories 2014, 13:115 Page 9 of 9
http://www.microbialcellfactories.com/content/13/1/115Escherichia coli enterotoxin B subunit (EtxB) to CD4(+) T cells.
Int Immunol 2001, 13:541–551.
43. Isticato R, Cangiano G, De Felice M, Ricca E: Display of Molecules on the
Spore Surface. In Bacterial Spore Formers. Edited by Ricca E, Henriques AO,
Cutting SM. Norfolk, UK: Horizon Biosience; 2004:193–200.
44. Pesce G, Rusciano G, Sirec T, Isticato R, Sasso A, Ricca E: Surface charge and
hydrodynamic coefficient measurements of Bacillus subtilis spore by
optical tweezers. Colloids Surf B Biointerfaces 2014, 116C:568–575.
45. Nguyen VA, Huynh HA, Hoang TV, Ninh NT, Pham AT, Nguyen HA, Phan TN,
Cutting SM: Killed Bacillus subtilis spores expressing streptavidin: a novel
carrier of drugs to target cancer cells. J Drug Target 2013, 21:528–541.
doi:10.1186/s12934-014-0115-2
Cite this article as: Ricca et al.: Mucosal vaccine delivery by non-
recombinant spores of Bacillus subtilis. Microbial Cell Factories 2014 13:115.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
